Evidence map›Paper›PMID 26967284›Full record

ReviewCell2016

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators.

Mark A Lemmon, Daniel M Freed, Joseph Schlessinger, Anatoly Kiyatkin

Abstract readReview
In one paragraph

Review in Cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Article
  2. Type 1 diabetesNPJ autoimmunity · 2026
    Article
  3. Design principles of ciliary signaling.Journal of cell science · 2025
    Review
  4. Article
  5. Famotidine increases cellular phospho-tyrosine levels.Biochemical and biophysical research communications · 2024
    Article
  6. Article
  7. Identification of key genes and molecular mechanisms of chronic urticaria based on bioinformatics.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mark A LemmonDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, West Haven, CT 06516, USA. Electronic address: mark.lemmon@yale.edu.
Daniel M FreedDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, West Haven, CT 06516, USA.
Joseph SchlessingerDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, West Haven, CT 06516, USA.
Anatoly KiyatkinDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, West Haven, CT 06516, USA.

Funding

PSOC@Penn Education and OutreachU54CA193417 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DISCHER, DENNIS E. · 2015 to 2020
$10.5M
Understanding EGF receptor activation by growth factors and oncogenic mutationsR01CA198164 · NCI · YALE UNIVERSITY · PI FERGUSON, KATHRYN M, LEMMON, MARK A · 2015 to 2024
$5.2M
Understanding Wnt signaling through Ror and Ryk family receptor tyrosine kinasesR01GM107435 · NIGMS · YALE UNIVERSITY · PI LEMMON, MARK A · 2013 to 2016
$2.2M
Signaling by growth factor receptors with intracellular pseudokinase domainsR01GM099891 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI LEMMON, MARK A · 2012 to 2015
$1.6M
EGFR in a sticky situation: probing structural transitions in dimerized receptorsF32GM109688 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI FREED, DANIEL M · 2014 to 2015
$106k
NCI NIH HHS R01 CA198164NCI NIH HHS R01-CA198164NCI NIH HHS U54 CA193417NCI NIH HHS U54-CA193417NIGMS NIH HHS F32 GM109688NIGMS NIH HHS F32-GM109688NIGMS NIH HHS R01 GM099891NIGMS NIH HHS R01-GM099891NIGMS NIH HHS R01 GM107435NIGMS NIH HHS R01-GM107435
6 · The paper itself

Abstract

Cell signaling is dominated by analyzing positive responses to stimuli. Signal activation is balanced by negative regulators that are generally considered to terminate signaling. Rather than exerting only negative effects, however, many such regulators play important roles in enhancing cell-signaling control. Considering responses downstream of selected cell-surface receptors, we discuss how receptor internalization affects signaling specificity and how rapid kinase/phosphatase and GTP/GDP cycles increase responsiveness and allow kinetic proofreading in receptor signaling. We highlight the blurring of distinctions between positive and negative signals, recasting signal termination as the response to a switch-like transition into a new cellular state.

Indexed as

Signal TransductionAnimalsFeedback, PhysiologicalHumansPhosphorylationReceptor Protein-Tyrosine KinasesReceptors, G-Protein-CoupledReceptor Protein-Tyrosine KinasesReceptors, G-Protein-Coupled

Identifiers

PMID26967284
PMCPMC4830124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.